Cargando…

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide

Hematopoietic stem-cell transplantation (HCT) and stem-cell–based gene therapies rely on the ability to collect sufficient CD34+ hematopoietic stem and progenitor cells (HSPCs), typically via peripheral blood mobilization. Commonly used HSPC mobilization regimens include single-agent granulocyte col...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crees, Zachary D., Rettig, Michael P., DiPersio, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214082/ https://www.ncbi.nlm.nih.gov/pubmed/37250913 http://dx.doi.org/10.1177/20406207231174304

Ejemplares similares

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
por: Crees, Zachary D., et al.
Publicado: (2023)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor
por: Rebolledo-Bustillo, Mariana, et al.
Publicado: (2023)

Mobilized peripheral blood: an updated perspective
por: Karpova, Darja, et al.
Publicado: (2019)

Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
por: Xiang, Jingyu, et al.
Publicado: (2022)

A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys
por: Fang, Xiao, et al.
Publicado: (2021)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
por: Kim, Miriam Y., et al.
Publicado: (2021)

Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis
por: Crees, Zachary D., et al.
Publicado: (2023)

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
por: Broxmeyer, Hal E., et al.
Publicado: (2005)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Suicide genes: monitoring cells in patients with a safety switch
por: Eissenberg, Linda G., et al.
Publicado: (2014)

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
por: Karpova, Darja, et al.
Publicado: (2017)

Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
por: Alahmari, Bader, et al.
Publicado: (2018)

Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587
por: Peng, Sheng-Bin, et al.
Publicado: (2017)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranolol
por: Sukhtankar, Devki D., et al.
Publicado: (2023)

Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization
por: Freitas, Christelle, et al.
Publicado: (2017)

Homing in hematopoietic stem cells: focus on regulatory role of CXCR7 on SDF1a/CXCR4 axis
por: Asri, Amir, et al.
Publicado: (2016)

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
por: Slade, Michael, et al.
Publicado: (2016)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

CXCR4 is required for the quiescence of primitive hematopoietic cells
por: Nie, Yuchun, et al.
Publicado: (2008)

Mouse models of graft-versus-host disease: advances and limitations
por: Schroeder, Mark A., et al.
Publicado: (2011)

Novel Roles for α3β1 Integrin as a Regulator of Cytoskeletal Assembly and as a Trans-dominant Inhibitor of Integrin Receptor Function in Mouse Keratinocytes
por: Hodivala-Dilke, Kairbaan M., et al.
Publicado: (1998)

A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML)
por: Uy, Geoffrey, et al.
Publicado: (2014)

Novel Bivalent and D-Peptide Ligands of CXCR4 Mobilize Hematopoietic Progenitor Cells to the Blood in C3H/HeJ Mice
por: Mao, Yujia, et al.
Publicado: (2018)

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment
por: Longmate, Whitney, et al.
Publicado: (2017)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Hematopoietic stem cell mobilization
por: Chang, Hsin-Hou, et al.
Publicado: (2021)

Differential CXCR4 expression on hematopoietic progenitor cells versus stem cells directs homing and engraftment
por: Felker, Sydney, et al.
Publicado: (2022)

In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [(18)F]FDG and [(64)Cu]Cu-LLP2A PET
por: Ghai, Anchal, et al.
Publicado: (2021)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

CXCR4-Related Increase of Circulating Human Lymphoid Progenitors after Allogeneic Hematopoietic Stem Cell Transplantation
por: Glauzy, Salomé, et al.
Publicado: (2014)

Small Molecule Inhibitors of CXCR4
por: Debnath, Bikash, et al.
Publicado: (2013)

AMD3100/CXCR4 Inhibitor
por: De Clercq, Erik
Publicado: (2015)

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period
por: Dubberke, Erik R., et al.
Publicado: (2017)

CXCR4 Antagonists as Stem Cell Mobilizers and Therapy Sensitizers for Acute Myeloid Leukemia and Glioblastoma?
por: Hira, Vashendriya V.V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6n0topur9jf24u0g25v2oi0a1e